QLT says phase 2 lemuteporfin-injectable trial failed to meet primary endpoint

By E. Janene Geiss

Philadelphia, Feb. 14 - QLT Inc. announced Tuesday that a phase 2 clinical trial of lemuteporfin-injectable in patients with benign prostatic hyperplasia did not meet the study's primary efficacy objective at three months.

While the decrease in American Urological Association Symptom Score was consistent with that seen after other minimally invasive therapies, there was no significant difference between treatment and sham-control groups, according to a company news release.

"The preliminary result of this trial does not support initiation of phase 3 clinical trials of lemuteporfin in benign prostatic hyperplasia at this time," Bob Butchofsky, QLT's acting chief executive officer, said in the release.

"We intend to complete the analysis of the data, including the six-month measurements, in order to determine the best path forward," he added.

QLT said it will discuss these results Feb. 22 during its previously scheduled investor conference call to discuss year-end results and 2006 guidance.

QLT is a Vancouver, B.C., biopharmaceutical company specializing in developing treatments for eye diseases as well as dermatological and urological conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.